Riskpilot← Back to searchSign inGet full accessRangers Pharmaceutical A/S
A/SIn liquidationCVR 40381015Pilestræde 58Growing of spices, aromatic, drug and pharmaceutical crops · NACE 0128Est. 20191 employees
Revenue 2024
DKK -90K
-61% vs 2023
EBITDA margin
100.0%
+61% vs 2023
Equity ratio
-12491.3%
Financial strength
Net profit 2024
DKK 1,6M
+32% vs 2023
| Revenue | DKK -90K | -61% |
| EBITDA | DKK -90K | +61% |
| Net profit | DKK 1,6M | +32% |
| Total assets | DKK 406K | -3% |
| Equity | DKK -50,8M | +3% |
| Employees | 1 | — |
Legal name
Rangers Pharmaceutical A/S
CVR number
40381015
Legal form
Aktieselskab
NACE code
0128 · Growing of spices, aromatic, drug and pharmaceutical crops
Founded
26. marts 2019
Share capital
DKK 400.003
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at dyrke cannabis til medicinsk brug
Address
Pilestræde 58
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -302 | -2.732 | -1.124 | -232 | -90 |
| Staff expenses | -391 | -0 | -0 | -0 | -0 |
| EBITDA | -4.034 | -2.732 | -50.136 | -232 | -90 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -4.034 | -2.732 | -50.136 | -232 | -90 |
| Net financials | -32 | 5 | -2.975 | 1.477 | 1.732 |
| Profit before tax | -4.067 | -2.726 | -53.111 | 1.245 | 1.641 |
| Tax | -1 | -0 | -0 | -0 | -0 |
| Net profit | -4.066 | -2.726 | -53.111 | 1.245 | 1.641 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 46 | 59.941 | 555 | 421 | 406 |
| Equity | -829 | -533 | -53.644 | -52.399 | -50.758 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 876 | 60.474 | 54.199 | 52.820 | 51.164 |
| Total debt | 876 | 60.474 | 54.199 | 52.820 | 51.164 |
EBITDA margin
-9040100.0%
This company
15.8%
Market median
-57215923% vs market
20202024
Equity ratio
-12491.3%
This company
38.2%
Market median
-32800% vs market
20202024
Return on equity
164128700.0%
This company
18.4%
Market median
+892003704% vs market
20202024
Net profit margin
164128700.0%
This company
8.1%
Market median
+2026280147% vs market
20202024
Asset turnover
-0.22×
This company
1.12×
Market median
-120% vs market
20202024
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NL Unofficial title | Unofficial title | 2025 |
| Former (2) | ||
MN Chief Executive Officer | Chief Executive Officer | 2019 – 2020 |
PM Management | Management | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Former (12) | ||
| Chairman | 2019 – 2019 | |
| Chairman | 2022 – 2023 | |
| Board of Directors | 2019 – 2019 | |
| Board of Directors | 2019 – 2021 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2019 – 2019 | |
| Chairman | 2019 – 2020 | |
| Board of Directors | 2023 – 2025 | |
| Chairman | 2020 – 2021 | |
| Board of Directors | 2021 – 2023 | |
| Chairman | 2023 – 2025 | |
| Board of Directors | 2019 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Rangers Pharmaceutical A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Niels Løber | Unofficial title | 0 companies |
| Morten Nøhr Mortensen | Chief Executive Officer | 0 companies |
| Peter Møller Lassen | Management | 0 companies |
| Jakob Schilder-Knudsen | Chairman | 0 companies |
| Farhan Lalani | Chairman | 0 companies |
| John Lindsay Joseph McKenna | Board of Directors | 0 companies |
| Selcuk Copkayaoglu | Board of Directors | 0 companies |
| Heinz Kvottrup Lorentzen | Board of Directors | 0 companies |
| Dmitry Zaytsev | Board of Directors | 0 companies |
| Clifford Starke | Chairman | 0 companies |
| Michael James Rank | Board of Directors | 0 companies |
| Thileepan Ananthakumaran | Chairman | 0 companies |
| Selcuk Copkayaoglu | Board of Directors | 0 companies |
| Dany Vaiman | Chairman | 0 companies |
| Thileepan Ananthakumaran | Board of Directors | 0 companies |